Method for Directed Intranasal Administration of a Composition

• US 20100137940A1
• Filed: 01/06/2010
• Published: 06/03/2010
• Est. Priority Date: 07/21/1997
• Status: Active Grant

• Current Assignee: BHL Patent Holdings LLC
• Original Assignee: Bruce H. Levin
• Inventors: Levin, Bruce H.
• Granted Patent: US 8,224,438 B2
• Time in Patent Office: Days
• US Class Current: 607/46
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/167 having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• CPC Class Codes: A61K 31/245 Amino benzoic acid types, e.g. procaine, novocaine salicylic acid esters A61K31/60
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 31/46 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
• CPC Class Codes: A61K 31/618 having the carboxyl group in position 1 esterified, e.g. salsalate
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0043 Nose
• CPC Class Codes: A61M 15/08 Inhaling devices inserted into the nose
• CPC Class Codes: A61M 2205/075 Bulb type
• CPC Class Codes: A61M 2210/0618 Nose
• CPC Class Codes: A61M 2230/005 Parameter used as control input for the apparatus
• CPC Class Codes: A61M 31/00 Devices for introducing or retaining media, e.g. remedies, in cavities of the body A61M25/00 takes precedence ; introducing or retaining ophthalmic products into the ocular cavities A61F9/0008
• CPC Class Codes: A61N 1/0546 Nasal electrodes
• CPC Class Codes: A61N 1/0551 Spinal or peripheral nerve electrodes
• CPC Class Codes: A61N 1/36075 Headache or migraine
• CPC Class Codes: A61N 5/00 Radiation therapy ultrasound therapy A61N7/00; devices or apparatus applicable to both therapy and diagnosis A61B6/00

Abstract

Methods, kits, apparatus, and compositions for inhibiting a cerebral neurovascular disorder, a muscular headache, or cerebral inflammation in a human patient are provided. The methods comprise intranasally administering to the patient a pharmaceutical composition comprising a local anesthetic, and preferably a long-acting local anesthetic ingredient. A composition useful for practicing the methods of the invention is described which comprises at least one local anesthetic in a pharmaceutically acceptable carrier, wherein the composition is formulated for intranasal delivery. Cerebral neurovascular disorders include migraine and cluster headache. Muscular headaches include tension headaches and muscle contraction headaches. A kit comprising the composition and an intranasal applicator and a method of systemically delivering a pharmaceutically active agent to an animal are also included in the invention. Apparatus for directed intranasal administration of the compositions of the invention and for performing the methods of the invention are also described.

Claims

1. A method of inhibiting a cerebral neurovascular disorder in a human patient, the method comprising implanting an electronic neural stimulator in patient tissue adjacent a dorsonasal nerve structure and energizing the implanted electronic neural stimulator, so as to inhibit the cerebral neurovascular disorder.

2. The method of claim 1 wherein the dorsonasal nerve structure is an SPG or branch thereof.

3. The method of claim 1 further comprising providing power to the implanted electronic neural stimulator using an external power supply.

4. The method of claim 3 wherein the step of providing power comprises inductively coupling the external power supply to the electronic neural stimulator.

5. The method of claim 1 further comprising effecting nerve block of the dorsonasal nerve structure.

6. A method of inhibiting a cerebral neurovascular disorder in a human patient, the method comprising applying at least one of an electrical potential and electromagnetic radiation to anesthetize a nerve structure associated with the cerebral neurovascular disorder and thereby inhibit the cerebral neurovascular disorder.

7. The method of claim 6, wherein the cerebral neurovascular disorder is cephalic inflammation.

8. The method of claim 6, wherein the electromagnetic radiation is radio frequency radiation.